AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models
Zhaomei Mu*, Teresa Klinowska, Xiaoshen Dong, Emily Foster, Chris Womack, Sandra V. Fernandez, Massimo Cristofanilli
Dive into the research topics of 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models'. Together they form a unique fingerprint.